Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Kura Oncology (KURA) Interest Expenses (2023 - 2026)

Kura Oncology has reported Interest Expenses over the past 4 years, most recently at $336000.0 for Q1 2026.

  • Quarterly Interest Expenses fell 12.04% to $336000.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $1.5 million through Mar 2026, down 8.55% year-over-year, with the annual reading at $1.5 million for FY2025, 6.61% down from the prior year.
  • Interest Expenses was $336000.0 for Q1 2026 at Kura Oncology, down from $346000.0 in the prior quarter.
  • Over five years, Interest Expenses peaked at $412000.0 in Q3 2024 and troughed at $336000.0 in Q1 2026.
  • The 4-year median for Interest Expenses is $393000.0 (2025), against an average of $385846.2.
  • Year-over-year, Interest Expenses rose 9.34% in 2024 and then decreased 14.14% in 2025.
  • A 4-year view of Interest Expenses shows it stood at $394000.0 in 2023, then grew by 2.28% to $403000.0 in 2024, then decreased by 14.14% to $346000.0 in 2025, then dropped by 2.89% to $336000.0 in 2026.
  • Per Business Quant, the three most recent readings for KURA's Interest Expenses are $336000.0 (Q1 2026), $346000.0 (Q4 2025), and $393000.0 (Q3 2025).